Gaby Galvin
Reporter
Gaby Galvin previously worked at Morning Consult as a reporter covering health.
-
Surprise Medical Bills Have Been Banned Since January. 1 in 5 Americans Say They or Their Family Have Gotten an Unexpected Charge Anyway
Survey highlights confusion around ban’s protections, health care price transparency
-
Novavax’s Traditional Vaccine for COVID-19 Could Hit the U.S. Soon. Most Unvaccinated Adults Wouldn’t Be Swayed
Biotech’s protein-based shot may find warmer reception as a booster dose for the vaccinated
-
About 2 in 3 Voters Back FDA Bans on Tobacco-Flavored Vapes
Findings come after agency orders all Juul products off the U.S. market
-
Half of Voters Disapprove of Supreme Court Ruling to Overturn Roe v. Wade
Survey comes amid health care, political fallout of decision to revoke federal abortion rights
-
Parents Aren’t Jumping to Get Their Babies, Toddlers Vaccinated
Survey indicates many parents still have questions about shots for kids under 5
-
After Slow Start, States Are Flush With COVID-19 Antiviral Pills. But Federal Data Shows Some Are Slow to Give Them Out
Georgia and Mississippi have dispensed just 16% of doses from U.S. government
-
More Than Half of U.S. Abortions Are Done With Pills. Americans Don’t Know Much About Them
Public views medication abortion as less safe than surgical procedure, despite low risks of either option
-
With Pandemic-Era Obamacare Subsidies in Flux, State Marketplaces Prep for Premium Surges, Coverage Disruptions
Democratic lawmakers are pushing leadership to pass an extension of the enhanced subsidies ahead of midterms
-
What’s to Blame for the Baby Formula Shortage? According to Voters, It’s Mostly Supply Chain Issues
More than half of voters pin blame for baby formula shortage on supply chain, FDA, Abbott
-
As Biden Signals Crackdown on Private Equity in Nursing Homes, Exclusive Analysis Shows PE Health Care Provider Deals Hit a High in 2021
Provider deals have slowed in early 2022, but analysts project a full-year outlook of increased interest from private equity buyers